WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (NASDAQ:MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of its best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The offering is expected to close on October 30, 2024, subject to satisfaction of customary closing conditions.
Janus Henderson Investors, RA Capital Management, L.P. and other notable growth and life science investors participated in the offering.
Rodman & Renshaw LLC is acting as the exclusive placement agent for the offering.
Monopar Therapeutics intends to use the net proceeds from the offering for general corporate purposes, which may include research and development expenditures, clinical trial expenditures, manufacture and supply of product and working capital.
The securities are being offered and sold pursuant to a “shelf” registration statement on Form S-3 (File No. 333-268935), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 21, 2022, and declared effective on January 4, 2023. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC and is available on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the …
Full story available on Benzinga.com
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (NASDAQ:MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of its best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The offering is expected to close on October 30, 2024, subject to satisfaction of customary closing conditions.
Janus Henderson Investors, RA Capital Management, L.P. and other notable growth and life science investors participated in the offering.
Rodman & Renshaw LLC is acting as the exclusive placement agent for the offering.
Monopar Therapeutics intends to use the net proceeds from the offering for general corporate purposes, which may include research and development expenditures, clinical trial expenditures, manufacture and supply of product and working capital.
The securities are being offered and sold pursuant to a “shelf” registration statement on Form S-3 (File No. 333-268935), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 21, 2022, and declared effective on January 4, 2023. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC and is available on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the …
Full story available on Benzinga.com
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (NASDAQ:MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of its best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The offering is expected to close on October 30, 2024, subject to satisfaction of customary closing conditions.
Janus Henderson Investors, RA Capital Management, L.P. and other notable growth and life science investors participated in the offering.
Rodman & Renshaw LLC is acting as the exclusive placement agent for the offering.
Monopar Therapeutics intends to use the net proceeds from the offering for general corporate purposes, which may include research and development expenditures, clinical trial expenditures, manufacture and supply of product and working capital.
The securities are being offered and sold pursuant to a “shelf” registration statement on Form S-3 (File No. 333-268935), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 21, 2022, and declared effective on January 4, 2023. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC and is available on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the …Full story available on Benzinga.com Read MoreMNPR, News, IPOs, Press Releases IPOs
